To: David who wrote (14528 ) 8/24/1999 4:05:00 PM From: David Respond to of 26039
Where is BioLogon 2.0? I am getting tired of waiting for this upgrade, and it looks like IDX is not going to move very much until it appears. Right now, we are seeing OK but nonetheless somewhat slower than expected CPQ sales of BioLogin 1.0 + hardware. There even have been suggestions on Yahoo that the CPQ sales channel is clogged. Why is that? Why haven't we seen any new OEMs for scanners? Maybe because BioLogon 2.0 and the DFR-300 are overhanging the market. If you were HP or IBM, wouldn't you want to introduce biometric security with the up to date equipment, rather than the line CPQ has been offering for a year? Like I said before, I am getting tired of waiting -- especially in light of the IDT history of pronouncements on this subject. Back in December 1998, it was reported that BioLogon 2.0 would come out in the first quarter of this year. Didn't happen. Then, the April 19, 1999, Computer Reseller News quoted Grant Evans as saying that BioLogon 2.0 would ship "later this month." Didn't happen, and you'd think that such a short range promise could be relied upon. However, later that month, a poster on this thread reported that an IDT spokesman (I believe it was Grant Evans again) held up a small fingerscanning device at an H&Q conference and said IDX would be selling it for $10 . . . surely, the DFR-300. See posts 13304 and 13318. I got an independent confirmation of this event from another source, as well. When someone from this thread contacted IDX IR, Chrissie Fowler denied it had happened. OK, so I guess that was an unauthorized release of new technology that was available to the select few at the H&Q conference, but not to the public. But it happened. Then on May 20, IDX released a 'press advisory' at the CTST conference that discussed BioLogon 2.0 features. And then Fowler discussed it at the last conference call, including the existence of numerous beta sites. If this new equipment is overhanging the market, we sure know who to blame. IDX. What's the point of this teasing if the company can't actually make it available? Are we gaining anything from this strategy, or does it just frustrate the stockholders and create some cynicism among the analysts? I'm not after Chrissie Fowler on this one. She's the press secretary, and has to field the calls. I want to know why Grant Evans is doing this talking when he can't back it up with action.